BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, March 29, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Feb. 16, 2011
View Archived Issues
Yale University scientists synthesize the aglycon of lomaiviticin A, a promising anticancer agent
Read More
Acacia Pharma completes phase I APD-515 trial for xerostomia in advanced cancer
Read More
Medivir begins phase Ia trial of HCV polymerase inhibitor TMC-649128
Read More
Bombesin BB2 receptor antagonist 77427 shows promise in preclinical models of asthma
Read More
Gap junction alpha-1 protein is a marker of prognosis in prostate cancer
Read More
First-in-class antibiotic RNPA-1000 inhibits bacterial turnover of RNA
Read More
Genotype of polymorphic SLC6A4 gene variants modulates effects of cocaine in vitro
Read More
Endoribonuclease Dicer is a potential target for geographic atrophy
Read More
New neuraminidase inhibitors claimed at University of British Columbia
Read More
AtheroNova advances preclinical evaluation of agents for atherosclerosis
Read More
Astellas Pharma withdraws MAA for darexaban in Japan
Read More
Adventrx to acquire SynthRx and purified poloxamer-188 for sickle cell disease
Read More
SYGNIS Pharma licenses European patent rights to AX-200
Read More
Crofelemer is safe and efficacious in phase II trial in adults with watery diarrhea
Read More
Lymphoseek phase III trial in breast cancer and melanoma reaches accrual objective
Read More
Australian scientists claim novel inhibitors of neuraminidase
Read More
Apricus licenses Vitaros to Neopharm in Israel and Palestinian territories
Read More
Alkermes reports phase II data on ALKS-37 in opioid-induced bowel dysfunction
Read More
Lundbeck donates certain rights regarding Lu-AE58479 to NINDS
Read More
New inhibitors claimed of MEKK 5
Read More
FDA accepts Acurox NDA filing and grants priority review
Read More
Sanofi-aventis to acquire Genzyme
Read More
Treatment begins in phase III trial of rHuPH20-delivered MabThera in NHL
Read More
FDA requests additional development activities to support approval of Adventrx's ANX-514
Read More
Raptor Pharma reopens enrollment in phase III DR Cysteamine trial in nephropathic cystinosis
Read More